WASHINGTON, DC - APRIL 18: U.S. President Donald Trump reacts as he speaks in the Oval Office before signing an Executive Order April 18, 2026 in Washington, DC. The executive order directs the Food and Drug Administration to issue new guidance on the use of psychedelic drugs intended for clinical trials for U.S. veterans suffering from Post Traumatic Stress Disorder. (Photo by Tasos Katopodis/Getty Images)

Former Navy SEAL Marcus Lutrell speaks before US President Donald Trump signs an executive order in the Oval Office of the White House in Washington, DC on April 18, 2026. The executive order aims to further US federal medical research and clinical trials for certain psychedelic drugs. (Photo by Jim WATSON / AFP via Getty Images)

Administrator for the Centers for Medicare and Medicaid Services Mehmet Oz (L) speaks before US President Donald Trump signs an executive order in the Oval Office of the White House in Washington, DC on April 18, 2026. The executive order aims to further US federal medical research and clinical trials for certain psychedelic drugs.certain psychedelic drugs. (Photo by Jim WATSON / AFP via Getty Images)

US media personality Joe Rogan speaks before US President Donald Trump signs an executive order in the Oval Office of the White House in Washington, DC on April 18, 2026. The executive order aims to further US federal medical research and clinical trials for certain psychedelic drugs.certain psychedelic drugs. (Photo by Jim WATSON / AFP via Getty Images)

Director of the National Institutes of Health Jay Bhattacharya (3L) speaks before US President Donald Trump signs an executive order in the Oval Office of the White House in Washington, DC on April 18, 2026.. The executive order aims to further US federal medical research and clinical trials for certain psychedelic drugs.certain psychedelic drugs. (Photo by Jim WATSON / AFP via Getty Images)

(L/R) US Secretary of Health and Human Services Robert F. Kennedy Jr., and US media personality Joe Rogan look on as US President Donald Trump shakes hands with W. Bryan Hubbard, CEO of Americans for Ibogaine, during an executive order signing ceremony in the Oval Office of the White House in Washington, DC on April 18, 2026. The executive order aims to further US federal medical research and clinical trials for certain psychedelic drugs.certain psychedelic drugs. (Photo by Jim WATSON / AFP via Getty Images)

WASHINGTON, DC - APRIL 18: U.S. President Donald Trump speaks in the Oval Office before signing an Executive Order April 18, 2026 in Washington, DC. The executive order directs the Food and Drug Administration to issue new guidance on the use of psychedelic drugs intended for clinical trials for U.S. veterans suffering from Post Traumatic Stress Disorder. (Photo by Tasos Katopodis/Getty Images)

WASHINGTON, DC - APRIL 18: U.S. President Donald Trump speaks in the Oval Office before signing an Executive Order April 18, 2026 in Washington, DC. The executive order directs the Food and Drug Administration to issue new guidance on the use of psychedelic drugs intended for clinical trials for U.S. veterans suffering from Post Traumatic Stress Disorder. (Photo by Tasos Katopodis/Getty Images)